Skip to content
- Bharat Biotech has said that its nasal vaccine against COVID-19, iNCOVACC, will be available to the public from the fourth week of January 2023.
- The Hyderabad-based biotechnology company said the vaccine would cost Rs 800 for private markets and Rs 325 for governments.
- Bharat Biotech’s INCOVACC is the world’s first intranasal COVID vaccine to receive approval for a primary 2-dose schedule as well as heterologous booster doses.
- The nasal vaccine will be offered as a booster dose for those over the age of 18. iNCOVACC has been developed by Bharat Biotech in partnership with the University of Washington, USA.